SK283927B6 - 1,8-Anelované chinolinónové deriváty substituované N- alebo C- viazanými imidazolmi inhibujúce farnezyl transferázu, spôsob ich výroby, medziprodukt na spôsob ich výroby a spôsob výroby medziproduktov a farmaceutický prostriedok obsahujúci tieto deriváty - Google Patents

1,8-Anelované chinolinónové deriváty substituované N- alebo C- viazanými imidazolmi inhibujúce farnezyl transferázu, spôsob ich výroby, medziprodukt na spôsob ich výroby a spôsob výroby medziproduktov a farmaceutický prostriedok obsahujúci tieto deriváty Download PDF

Info

Publication number
SK283927B6
SK283927B6 SK1217-99A SK121799A SK283927B6 SK 283927 B6 SK283927 B6 SK 283927B6 SK 121799 A SK121799 A SK 121799A SK 283927 B6 SK283927 B6 SK 283927B6
Authority
SK
Slovakia
Prior art keywords
formula
hydrogen
chlorophenyl
mixture
alkyl
Prior art date
Application number
SK1217-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK121799A3 (en
Inventor
Marc Gaston Venet
Patrick Ren Angibaud
Yannick Aim� Eddy Ligny
Virginie Sophie Poncelet
G�Rard Charles Sanz
Original Assignee
Janssen Pharmaceutica N. V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N. V. filed Critical Janssen Pharmaceutica N. V.
Publication of SK121799A3 publication Critical patent/SK121799A3/sk
Publication of SK283927B6 publication Critical patent/SK283927B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1217-99A 1997-03-10 1998-03-03 1,8-Anelované chinolinónové deriváty substituované N- alebo C- viazanými imidazolmi inhibujúce farnezyl transferázu, spôsob ich výroby, medziprodukt na spôsob ich výroby a spôsob výroby medziproduktov a farmaceutický prostriedok obsahujúci tieto deriváty SK283927B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97200709 1997-03-10
EP97200708 1997-03-10
PCT/EP1998/001296 WO1998040383A1 (en) 1997-03-10 1998-03-03 Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with n- or c-linked imidazoles

Publications (2)

Publication Number Publication Date
SK121799A3 SK121799A3 (en) 2000-05-16
SK283927B6 true SK283927B6 (sk) 2004-05-04

Family

ID=26146222

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1217-99A SK283927B6 (sk) 1997-03-10 1998-03-03 1,8-Anelované chinolinónové deriváty substituované N- alebo C- viazanými imidazolmi inhibujúce farnezyl transferázu, spôsob ich výroby, medziprodukt na spôsob ich výroby a spôsob výroby medziproduktov a farmaceutický prostriedok obsahujúci tieto deriváty

Country Status (22)

Country Link
US (2) US6187786B1 (xx)
EP (1) EP0970079B1 (xx)
JP (1) JP4272262B2 (xx)
KR (1) KR100549096B1 (xx)
CN (1) CN1128797C (xx)
AT (1) ATE251159T1 (xx)
AU (1) AU748702B2 (xx)
BR (1) BR9808843A (xx)
CA (1) CA2283587C (xx)
DE (1) DE69818649T2 (xx)
ES (1) ES2209127T3 (xx)
HK (1) HK1024689A1 (xx)
HU (1) HUP0001498A3 (xx)
IL (1) IL130362A (xx)
NO (1) NO313143B1 (xx)
NZ (1) NZ336234A (xx)
PL (1) PL191564B1 (xx)
RU (1) RU2204553C2 (xx)
SK (1) SK283927B6 (xx)
TR (1) TR199902203T2 (xx)
TW (1) TW591030B (xx)
WO (1) WO1998040383A1 (xx)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
DK1097150T3 (da) * 1998-06-16 2004-07-26 Sod Conseils Rech Applic Imidazolylderivater
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
TR200003882T2 (tr) * 1998-07-06 2001-06-21 Janssen Pharmaceutica N.V. Artropatilerin tedavisi için farnesil protein transferaz inhibitörleri.
EA003877B1 (ru) 1998-07-06 2003-10-30 Янссен Фармацевтика Н.В. Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
CA2341739C (en) * 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
AU2478500A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000034437A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EE04962B1 (et) * 1998-12-23 2008-02-15 Janssen Pharmaceutica N.V. Kinoliini ühend, seda sisaldav farmatseutiline kompositsioon, ühendi kasutamine ravimina ning meetod ühendi ja kompositsiooni valmistamiseks
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (en) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
ES2304996T3 (es) 1999-11-15 2008-11-01 Janssen Pharmaceutica Nv Triazoles como inhibidores de farnesil transferasa.
ATE259365T1 (de) * 1999-11-30 2004-02-15 Pfizer Prod Inc Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase
KR20010077400A (ko) * 2000-02-02 2001-08-17 성재갑 에프타아제 저해제인 엘비42908과 타(他) 항암제와의조합에 의한 항암치료제
SI1255537T1 (sl) * 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
US6838467B2 (en) 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
AU2001252147A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations
US20030212008A1 (en) * 2000-02-29 2003-11-13 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
JP2003525236A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ビンカアルカロイドとのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
JP2003525252A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
AU2001256166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
AU2001239275A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064199A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
JP2003525246A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
CA2397446A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
CA2397240A1 (en) * 2000-02-29 2001-09-07 Peter Albert Palmer Farnesyl protein transferase inhibitor combinations with camptothecin compounds
WO2001064197A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
CA2423060A1 (en) * 2000-09-21 2003-03-19 Takeda Chemical Industries, Ltd. Process for producing tricyclic fused heterocyclic derivative
AU2001293826A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
AU2001293829A1 (en) * 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
AU2001293835A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
JP4974438B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体
ATE434615T1 (de) 2000-11-21 2009-07-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
US20040044032A1 (en) * 2000-11-28 2004-03-04 End David William Farnesyl protein transfer inhibitors for the treatment of inflammatory bowel disease
DE60117847T2 (de) 2000-12-27 2006-11-16 Janssen Pharmaceutica N.V. Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
DE60230017D1 (de) * 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
DE60202755T2 (de) * 2001-03-12 2006-03-30 Janssen Pharmaceutica N.V. Verfahren zur herstellung von imidazolverbindungen
US7408063B2 (en) 2001-12-19 2008-08-05 Janssen Pharmaceutica, N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
CA2478813C (en) 2002-03-22 2011-10-18 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
AU2003229688B2 (en) 2002-04-15 2009-07-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
CA2536238C (en) 2003-08-18 2015-04-07 Medimmune, Inc. Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
PT1815247E (pt) 2004-11-05 2013-04-23 Janssen Pharmaceutica Nv Uso terapêutico de inibidores de farnesiltransferase e métodos para monitorizar a eficácia do mesmo
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
BRPI0710548B8 (pt) 2006-04-20 2021-05-25 Janssen Pharmaceutica Nv inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
AU2007240437B2 (en) 2006-04-20 2012-12-06 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
MX2009002151A (es) 2006-08-28 2009-07-03 Kirin Pharma Kk Anticuerpos monoclonales humanos especificos para light humano antagonistas.
EP2077859A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODY FORMULATION
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
BRPI0818810A2 (pt) 2007-10-31 2014-10-29 Medimmune Llc Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável.
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
CN105153188B (zh) * 2009-10-22 2018-06-01 法博太科制药有限公司 抗纤维化剂的稠环类似物
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
CN103328971B (zh) 2010-07-28 2016-09-28 维里德克斯有限责任公司 急性髓细胞性白血病应答法尼基转移酶抑制剂治疗的测定方法
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
JP6250684B2 (ja) * 2012-10-11 2017-12-20 メルク パテント ゲーエムベーハー 有機エレクトロルミネッセンス素子のための材料
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
KR20160054501A (ko) 2013-08-26 2016-05-16 맵백스 테라퓨틱스, 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015187811A2 (en) 2014-06-04 2015-12-10 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
ES2834739T3 (es) 2014-12-11 2021-06-18 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
DK3277842T5 (da) 2015-08-17 2020-08-31 Kura Oncology Inc Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20190082247A (ko) 2016-11-03 2019-07-09 쿠라 온콜로지, 인크. 파르네실전달효소 억제제를 이용하여 암 환자를 치료하는 방법
AU2018277838A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
US20200131266A1 (en) 2017-05-31 2020-04-30 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
MX2021000786A (es) 2018-07-20 2021-06-15 Pf Medicament Receptor para supresor de ig del dominio v de activación de células t (vista).
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008325A (en) * 1972-05-17 1977-02-15 Pfizer Inc. Control of rice blast disease employing certain pyrido compounds
GB1394373A (en) * 1972-05-17 1975-05-14 Pfizer Ltd Control of plant diseases
US4014883A (en) * 1973-09-10 1977-03-29 Hoffmann-La Roche Inc. Indoloquinolines, intermediates and processes
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
CA2002859C (en) 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
GB9212833D0 (en) 1992-06-17 1992-07-29 Glaxo Group Ltd Chemical compounds
TW316902B (xx) 1994-12-28 1997-10-01 Janssen Pharmaceutica Nv
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles

Also Published As

Publication number Publication date
US20020049327A1 (en) 2002-04-25
RU2204553C2 (ru) 2003-05-20
ES2209127T3 (es) 2004-06-16
WO1998040383A1 (en) 1998-09-17
NO994268D0 (no) 1999-09-02
BR9808843A (pt) 2000-07-04
AU748702B2 (en) 2002-06-13
KR100549096B1 (ko) 2006-02-06
NO313143B1 (no) 2002-08-19
EP0970079A1 (en) 2000-01-12
US6187786B1 (en) 2001-02-13
KR20000069559A (ko) 2000-11-25
SK121799A3 (en) 2000-05-16
PL191564B1 (pl) 2006-06-30
NO994268L (no) 1999-11-08
TW591030B (en) 2004-06-11
JP4272262B2 (ja) 2009-06-03
AU7031898A (en) 1998-09-29
JP2001515487A (ja) 2001-09-18
HUP0001498A2 (hu) 2000-11-28
DE69818649T2 (de) 2004-07-01
NZ336234A (en) 2000-10-27
HK1024689A1 (en) 2000-10-20
US6444812B1 (en) 2002-09-03
TR199902203T2 (xx) 1999-12-21
PL335518A1 (en) 2000-04-25
IL130362A0 (en) 2000-06-01
ATE251159T1 (de) 2003-10-15
HUP0001498A3 (en) 2001-01-29
CN1128797C (zh) 2003-11-26
CA2283587C (en) 2007-05-01
IL130362A (en) 2004-02-19
CN1249753A (zh) 2000-04-05
EP0970079B1 (en) 2003-10-01
DE69818649D1 (de) 2003-11-06
CA2283587A1 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
SK283927B6 (sk) 1,8-Anelované chinolinónové deriváty substituované N- alebo C- viazanými imidazolmi inhibujúce farnezyl transferázu, spôsob ich výroby, medziprodukt na spôsob ich výroby a spôsob výroby medziproduktov a farmaceutický prostriedok obsahujúci tieto deriváty
CZ293296B6 (cs) (Imidazol-5-yl)methyl-2-chinolinonové deriváty inhibující farnesyl protein transferázu
US6458800B1 (en) 1,2-annelated quinoline derivatives
PL190944B1 (pl) Pochodna chinazolinonu i sposób jej wytwarzania oraz kompozycja farmaceutyczna i sposób jej wytwarzania
EP1019395B1 (en) Farnesyl transferase inhibiting 2-quinolone derivatives
CZ316799A3 (cs) 1,8-Anelované chinolinonové deriváty substituované N- nebo C-vázanými imidazoly inhibující farnesyl transferázu
EP1458720B1 (en) 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors